Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

Literature DB >> 11960359

Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

K Deguchi¹, D G Gilliland.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2002 PMID： 11960359 DOI： 10.1038/sj.leu.2402500

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. De novo discovery of mutated driver pathways in cancer.

Authors: Fabio Vandin; Eli Upfal; Benjamin J Raphael
Journal: Genome Res Date: 2011-06-07 Impact factor: 9.043

Review 2. Myelodysplastic syndromes: an update on molecular pathology.

Authors: Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal: Clin Transl Oncol Date: 2010-10 Impact factor: 3.405

3. Proapoptotic BID is required for myeloid homeostasis and tumor suppression.

Authors: Sandra S Zinkel; Christy C Ong; David O Ferguson; Hiromi Iwasaki; Koichi Akashi; Roderick T Bronson; Jeffery L Kutok; Frederick W Alt; Stanley J Korsmeyer
Journal: Genes Dev Date: 2003-01-15 Impact factor: 11.361

4. High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Authors: Zhixiong Li; Gernot Beutel; Mathias Rhein; Johann Meyer; Christian Koenecke; Thomas Neumann; Min Yang; Jürgen Krauter; Nils von Neuhoff; Michael Heuser; Helmut Diedrich; Gudrun Göhring; Ludwig Wilkens; Brigitte Schlegelberger; Arnold Ganser; Christopher Baum
Journal: Blood Date: 2008-12-04 Impact factor: 22.113

Review 5. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors: Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal: Drug Resist Updat Date: 2007-05-07 Impact factor: 18.500

6. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor.

Authors: Anuradha Pradhan; Que T Lambert; Gary W Reuther
Journal: Proc Natl Acad Sci U S A Date: 2007-11-14 Impact factor: 11.205

Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

1. De novo discovery of mutated driver pathways in cancer.

Review 2. Myelodysplastic syndromes: an update on molecular pathology.

3. Proapoptotic BID is required for myeloid homeostasis and tumor suppression.

4. High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Review 5. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

6. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor.

7. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

8. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.

9. Cell cycle control in acute myeloid leukemia.

10. Applications of microarray technology to Acute Myelogenous Leukemia.